SI20270A - Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev - Google Patents

Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev Download PDF

Info

Publication number
SI20270A
SI20270A SI9820055A SI9820055A SI20270A SI 20270 A SI20270 A SI 20270A SI 9820055 A SI9820055 A SI 9820055A SI 9820055 A SI9820055 A SI 9820055A SI 20270 A SI20270 A SI 20270A
Authority
SI
Slovenia
Prior art keywords
oxo
carboxamide
naphthyridine
tetrahydro
compound according
Prior art date
Application number
SI9820055A
Other languages
English (en)
Slovenian (sl)
Inventor
Pamela Albaugh
Robert W. Desimone
Gang Liu
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of SI20270A publication Critical patent/SI20270A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9820055A 1997-08-25 1998-08-24 Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev SI20270A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
SI20270A true SI20270A (sl) 2000-12-31

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9820055A SI20270A (sl) 1997-08-25 1998-08-24 Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev

Country Status (24)

Country Link
EP (1) EP1007526A1 (no)
JP (1) JP2001514181A (no)
KR (1) KR20010023313A (no)
CN (1) CN1268136A (no)
AP (1) AP2000001742A0 (no)
AU (1) AU753800B2 (no)
BG (1) BG104192A (no)
BR (1) BR9811362A (no)
CA (1) CA2301599C (no)
EG (1) EG21717A (no)
HU (1) HUP0003258A3 (no)
IL (1) IL134291A0 (no)
IS (1) IS5382A (no)
LV (1) LV12539B (no)
NO (1) NO20000822L (no)
NZ (1) NZ502548A (no)
OA (1) OA11293A (no)
PE (1) PE130999A1 (no)
PL (1) PL338783A1 (no)
SI (1) SI20270A (no)
SK (1) SK2162000A3 (no)
TW (1) TW574221B (no)
WO (1) WO1999010347A1 (no)
YU (1) YU10500A (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010308A (pt) * 1999-05-06 2002-01-08 Neurogen Corp Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU1152702A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
ES2274913T3 (es) 2000-10-12 2007-06-01 MERCK & CO., INC. Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de vih integrada.
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
HUP0303448A3 (en) * 2001-03-01 2005-05-30 Pfizer Prod Inc Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
PT2074123E (pt) * 2006-10-16 2013-01-22 Bionomics Ltd Novos compostos ansiolíticos
HUE032743T2 (en) * 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
LV12539A (en) 2000-10-20
LV12539B (en) 2001-01-20
KR20010023313A (ko) 2001-03-26
HUP0003258A2 (en) 2001-03-28
JP2001514181A (ja) 2001-09-11
TW574221B (en) 2004-02-01
IS5382A (is) 2000-02-22
CA2301599A1 (en) 1999-03-04
EP1007526A1 (en) 2000-06-14
PE130999A1 (es) 1999-12-16
NO20000822L (no) 2000-04-13
CN1268136A (zh) 2000-09-27
NO20000822D0 (no) 2000-02-18
OA11293A (en) 2002-11-19
NZ502548A (en) 2002-06-28
YU10500A (sh) 2002-10-18
AU9117398A (en) 1999-03-16
AP2000001742A0 (en) 2000-02-24
EG21717A (en) 2002-02-27
AU753800B2 (en) 2002-10-31
BG104192A (en) 2001-05-31
PL338783A1 (en) 2000-11-20
CA2301599C (en) 2003-03-25
SK2162000A3 (en) 2001-03-12
HUP0003258A3 (en) 2001-05-28
BR9811362A (pt) 2000-08-22
IL134291A0 (en) 2001-04-30
WO1999010347A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
US6646124B2 (en) Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
US6103903A (en) 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
US6166203A (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
AU754716B2 (en) Amide derivatives and nociceptin antagonists
SI20270A (sl) Substituirani 4-okso-naftiridin-3-karboksamidi kot ligandi možganskih GABA receptorjev
US5840888A (en) Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
DE60214990T2 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
JPH06502639A (ja) 特定のイミダゾキノキサリン；新種のｇａｂａ脳受容体リガンド
MXPA01011173A (es) 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
US6194427B1 (en) Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
EP0650964A1 (en) 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
EP1107966B1 (en) Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands